The best-studied example of targeted therapies exploiting the synthetic lethality (SL) principle is the use of poly-ADP ribose polymerase (PARP) inhibitors in breast and ovarian cancer harboring mutations in BReast CAncer gene (BRCA). The gene discussed is PARP1; the disease is ovarian cancer.